No. As of September 2026, Alumis Inc. (ALMS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 33.6% / 30% · Interest income / Revenue 225.7% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 33.6% / 33% · Receivables / Mkt Cap (36m) 0.25% / 49% · Interest income / Revenue 225.7% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 33.6% / 33.33% · Receivables / Mkt Cap (24m) 0.25% / 33.33% · Interest income / Revenue 225.7% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.43% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 82.8% / 33.33% · Receivables / Avg Assets (4Q) 0.56% / 33.33% · Interest income / Revenue 225.7% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 88.3% / 33.33% · (Cash+Recv) / Total Assets 88.9% / 33.33% · Interest income / Revenue 225.7% / 5% | Fail |
No. As of September 2026, Alumis Inc. (ALMS) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Alumis Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 225.7% of each dividend: Alumis Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Alumis Inc. (NASDAQ: ALMS) is a Healthcare company (Biotechnology) with a market capitalization of $626M. The Maz Rating grades it against the other companies in its sector.
Alumis Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.84, Alumis Inc. trades at 84.5x sales and 1.6x book value. Over the last twelve months it generated about $7M of revenue and a net loss of $460M. It runs a gross margin of 88.0%, an operating margin of -6116.7% and a net margin of -5844.5%. It shows return on equity of -99.6%, return on invested capital of -106.4% and a free cash flow yield of -52.3%. On the balance sheet: a debt-to-equity ratio of 0.09 and a current ratio of 5.57. Over the past 52 weeks the share price ranged from $4.70 to $31.35, with a beta of -0.67.
Alumis Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 7 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.